Tag: Cancer Drugs

EC Approved BAVENCIO® for Advanced Renal Cell Carcinoma Treatment

merck kgaa
Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. announced that the European Commission (EC) has approved BAVENCIO® (av...

Seattle Genetics Ready to File Tucatinib

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease. The HER2CLIMB trial compar...

European Commission Approved Astellas Therapy XOSPATA™

drug-development
Astellas Pharma Inc. announced that the European Commission (EC) has approved the oral once-daily therapy XOSPATA™ (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or ...

BMS Gets EC Approval for Opdivo

bms
Bristol-Myers Squibb Company announced that the European Commission (EC) has approved Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused ...

GSK Secured FDA Approval for Zejula

gsk
GlaxoSmithKline (GSK) has secured expanded approval from the US Food and Drug Administration (FDA) for its Zejula (niraparib) for the late-line treatment for women with recurrent ovarian cancer. ...

Mabscale Began Clinical Trials of Trastuzumab Bio-Analog

clinical trials
The joint company of the Russian pharmaceutical enterprises Ozon and PharmEco, Mabscale, began clinical trials of a phase I comparison of a bio-analog of its own trastuzumab with the original Hercepti...

Roche Announced Positive Phase III Study of Tecentriq® in Combination with Avastin®

roche
Roche announced that the Phase III IMbrave150 study, evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinom...

Eli Lilly’s Cancer Drug Failed in Clinical Trials

eli lilly
Eli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in phase 3 pancreatic cancer trial. The big US pharma said top-line results from the phase 3 SEQUO...

Rucaparib Approved by NICE for Cancer Drugs Fund

cancer drugs
Rucaparib can now be offered to women with relapsed ovarian, fallopian tube or peritoneal cancer, that has responded to platinum-based chemotherapy. Taken as a tablet, twice daily, it slows the progre...

BMS Registered New Indication for Opdivo in Russia

Bristol-Myers Squibb Company announced that it has registered in Russia a new indication for the immuno-oncological drug Opdivo® (nivolumab), namely, as a monotherapy for common or recurrent cancer of...

Daiichi Sankyo Announced Launch of VANFLYTA® in Japan

Daiichi Sankyo Company, Limited announced the launch of VANFLYTA® (quizartinib), an oral FLT3 inhibitor, in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid le...

Eli Lilly Announced Positive Results from Phase 3 RELAY trial of CYRAMZA®

Eli Lilly and Company announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (NSC...

NICE Refused to Recommend Tecentriq by Roche for Triple Negative Breast Cancer Treatment

Draft guidance published by NICE does not recommend atezolizumab, Tecentriq by Roche, for treating people with a type of breast cancer that has spread to other parts of the body. Atezolizumab, give...

Eisai and Merck Announced Final Results from Study Evaluating LENVIMA plus KEYTRUDA

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 e...

Servier Announced Acquisition of PIXUVRI® from CTI BioPharma

Servier, an independent international pharmaceutical company, announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory a...

Roche Presented Positive Results from Phase III IMvigor130 Study Evaluating Tecentriq®

Roche presented positive results from the Phase III IMvigor130 study evaluating Tecentriq® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line (initial) treatm...